Cargando…
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903276/ https://www.ncbi.nlm.nih.gov/pubmed/35259162 http://dx.doi.org/10.1371/journal.pone.0257930 |
_version_ | 1784664726399090688 |
---|---|
author | Clark, Natasha M. Janaka, Sanath Kumar Hartman, William Stramer, Susan Goodhue, Erin Weiss, John Evans, David T. Connor, Joseph P. |
author_facet | Clark, Natasha M. Janaka, Sanath Kumar Hartman, William Stramer, Susan Goodhue, Erin Weiss, John Evans, David T. Connor, Joseph P. |
author_sort | Clark, Natasha M. |
collection | PubMed |
description | The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plasma (CCP) was a common means of passive immunization with a theoretical risk of antibody-dependent enhancement (ADE) of viral infection. Though vaccines elicit a strong and protective immune response and transfusion of CCP with high titers of neutralization activity are correlated with better clinical outcomes, the question of whether antibodies in CCP can enhance infection of SARS-CoV-2 has not been directly addressed. In this study, we analyzed for and observed passive transfer of neutralization activity with CCP transfusion. Furthermore, to specifically understand if antibodies against the spike protein (S) enhance infection, we measured the anti-S IgG, IgA, and IgM responses and adapted retroviral-pseudotypes to measure virus neutralization with target cells expressing the ACE2 virus receptor and the Fc alpha receptor (FcαR) or Fc gamma receptor IIA (FcγRIIA). Whereas neutralizing activity of CCP correlated best with higher titers of anti-S IgG antibodies, the neutralizing titer was not affected when Fc receptors were present on target cells. These observations support the absence of antibody-dependent enhancement of infection (ADE) by IgG and IgA isotypes found in CCP. The results presented, therefore, not only supports the therapeutic use of currently available antibody-based treatment, including the continuation of CCP transfusion strategies, but also the use of various vaccine platforms in a prophylactic approach. |
format | Online Article Text |
id | pubmed-8903276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89032762022-03-09 Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection Clark, Natasha M. Janaka, Sanath Kumar Hartman, William Stramer, Susan Goodhue, Erin Weiss, John Evans, David T. Connor, Joseph P. PLoS One Research Article The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plasma (CCP) was a common means of passive immunization with a theoretical risk of antibody-dependent enhancement (ADE) of viral infection. Though vaccines elicit a strong and protective immune response and transfusion of CCP with high titers of neutralization activity are correlated with better clinical outcomes, the question of whether antibodies in CCP can enhance infection of SARS-CoV-2 has not been directly addressed. In this study, we analyzed for and observed passive transfer of neutralization activity with CCP transfusion. Furthermore, to specifically understand if antibodies against the spike protein (S) enhance infection, we measured the anti-S IgG, IgA, and IgM responses and adapted retroviral-pseudotypes to measure virus neutralization with target cells expressing the ACE2 virus receptor and the Fc alpha receptor (FcαR) or Fc gamma receptor IIA (FcγRIIA). Whereas neutralizing activity of CCP correlated best with higher titers of anti-S IgG antibodies, the neutralizing titer was not affected when Fc receptors were present on target cells. These observations support the absence of antibody-dependent enhancement of infection (ADE) by IgG and IgA isotypes found in CCP. The results presented, therefore, not only supports the therapeutic use of currently available antibody-based treatment, including the continuation of CCP transfusion strategies, but also the use of various vaccine platforms in a prophylactic approach. Public Library of Science 2022-03-08 /pmc/articles/PMC8903276/ /pubmed/35259162 http://dx.doi.org/10.1371/journal.pone.0257930 Text en © 2022 Clark et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Clark, Natasha M. Janaka, Sanath Kumar Hartman, William Stramer, Susan Goodhue, Erin Weiss, John Evans, David T. Connor, Joseph P. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title_full | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title_fullStr | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title_full_unstemmed | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title_short | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection |
title_sort | anti-sars-cov-2 igg and iga antibodies in covid-19 convalescent plasma do not enhance viral infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903276/ https://www.ncbi.nlm.nih.gov/pubmed/35259162 http://dx.doi.org/10.1371/journal.pone.0257930 |
work_keys_str_mv | AT clarknatasham antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT janakasanathkumar antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT hartmanwilliam antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT stramersusan antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT goodhueerin antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT weissjohn antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT evansdavidt antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection AT connorjosephp antisarscov2iggandigaantibodiesincovid19convalescentplasmadonotenhanceviralinfection |